Webinar: Overcoming Roadblocks Making Psychedelic-Assisted Therapy a Reality

On the 31st of August 2022, our speakers dug deep into topics like how psychedelic-assisted therapy will become a reality and what the legislative and regulatory roadblocks will be.
ICPR 2022
A business event will take place prior to ICPR 2022. Find out more at icpr-conference.com
Livestream tickets for ICPR 2022 are now available!! Thanks for following us and reading this. With coupon code openlive30 you get 30 euro off live stream tickets at icpr-conference.com/tickets
Learn more about the OPEN Foundation at open-foundation.org
On this panel
Chris Koddermann (ITPRI - Reschedule Psilocybin), Amy Emerson (MAPS PBC), Tadeusz Hawrot (PAREA - Psychedelic Access and Research European Alliance), Graham Pechenik (Calyx Law) - moderated by Zach Haigney (The Trip Report) - are taking them down? When will psychedelic-assisted therapy become a reality in Europe and the US?
Amy Emerson is the CEO of MAPS Public Benefit Corporation, a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a non-profit. As CEO, Amy has led the growth and development of this new subsidiary. She is responsible for the overall global regulatory strategy and implementation of research programs with a focus on the MDMA-assisted psychotherapy program within MAPS PBC.
Amy has been advising MAPS since 2003 and has since built MAPS’ clinical department while managing the MDMA Clinical Development Program with a focus on the PTSD indication. Amy is passionate about being a mother and the work of bringing the potential of psychedelics for healing further into the consciousness of the world, leaving a better world for the following generations.
Chris Koddermann is the Co-founder and Chair of the Board of the International Therapeutic Psilocybin Rescheduling Initiative (ITPRI), a global coalition launched to pursue and secure a rescheduling of psilocybin under the 1971 Convention on Psychotropic Substances. In addition to his work with ITPRI, Christopher runs a Swiss-based communications, public relations and government affairs consultancy serving clients operating in complex, highly regulated industries, including for-profit and not-for-profit clients active in psychedelics. In addition to his other activities, Christopher is a member of Drug Science’s Medical Psychedelics Working Group. Christopher holds a Master’s degree in International Business Law from the London School of Economics and is a licenced attorney in the State of New York.
Tadeusz Hawrot has spent 15 years working in the EU environment, leading the policy and advocacy work of several civil society organisations in the field of brain health. He was instrumental in setting up new advocacy alliances such as the National Brain Councils, Portuguese Societal Impact of Pain Platform and a global partnership OneNeurology. He is cooperating with WHO and other global health advocates. He is the founder of the Psychedelic Access and Research European Alliance (PAREA).
Tadeusz is the Founder and Policy Lead of PAREA which advocates for stepping up the European Union’s efforts to thoroughly assess the medicinal benefits of psychedelic compounds as safe, effective, and cost-efficient therapies as well as to better understand and mitigate associated risks.
Graham Pechenik is a registered patent attorney and Founder of Calyx Law. He is working with businesses in the cannabis and psychedelics spaces to design and implement their patent strategy, and generate value and growth through intellectual property. When he's not working with clients, Graham contributes to Psychedelic Alpha as editor-at-large, where he writes about psychedelics IP, provides data for patent trackers, and helps maintain a psychedelics legalisation and decriminalisation tracker. Graham is also a member of Chacruna's Council for the Protection of Sacred Plants.